Department of Radiation Oncology, National University Hospital, National Cancer Institute of Singapore, Singapore, Singapore
Department of Radiation Oncology, National University Hospital, National Cancer Institute of Singapore, Singapore, Singapore.
In Vivo. 2019 Nov-Dec;33(6):2161-2167. doi: 10.21873/invivo.11718.
BACKGROUND/AIM: The aim of this study was to review the outcomes of palliative radiotherapy (RT) for hematuria treated with modern RT techniques.
This was a retrospective cohort study. The primary endpoint was symptom response rate. Secondary endpoints included symptom recurrence rate, overall survival and treatment-related toxicity.
Median age was 82 years (range=36-98 years). Median biologically effective dose (BED) was 36 Gy. Sixty-seven percent of patients (39/58) responded to RT. The median survival duration was 5.6 months (range=0.02-47.6 months). One third (13/39) of responders had recurrence of hematuria. Competing Risk regression with death as the competing risk showed that patients treated with low BED regimen (<36 Gy) had 5.76 times the hazard of recurrence compared to high BED regimen (>36 Gy) (p=0.01). One patient (2%) developed grade 3 nausea and vomiting which required admission for intravenous hydration.
BED regimens should be recommended as they are associated with a significantly lower rate of recurrent hematuria.
背景/目的：本研究旨在回顾采用现代放射治疗技术治疗血尿的姑息性放射治疗（RT）的结果。
这是一项回顾性队列研究。主要终点是症状缓解率。次要终点包括症状复发率、总生存率和与治疗相关的毒性。
中位年龄为 82 岁（范围=36-98 岁）。中位生物有效剂量（BED）为 36 Gy。67%的患者（39/58）对 RT 有反应。中位生存时间为 5.6 个月（范围=0.02-47.6 个月）。三分之一（13/39）的缓解者出现血尿复发。以死亡为竞争风险的竞争风险回归显示，接受低 BED 方案（<36 Gy）治疗的患者复发的风险是接受高 BED 方案（>36 Gy）治疗的患者的 5.76 倍（p=0.01）。有 1 名患者（2%）出现 3 级恶心和呕吐，需要入院接受静脉补液治疗。
推荐使用 BED 方案，因为它们与血尿复发率显著降低相关。
